Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20123359 | 0.91 | ATM (0.50) | ATMALDH1A1KMT2ALMNAGLA | |
| SCHEMBL15142912 | 0.91 | TSHR (0.51) | ATMALDH1A1KMT2ALMNAGAA | |
| SCHEMBL65273 | 0.89 | TDP1 (0.55) | ATMALDH1A1KMT2ALMNAGLA | |
| SCHEMBL16666715 | 0.89 | ATM (0.51) | ATMALDH1A1KMT2ALMNAGLA | |
| SCHEMBL63719 | 0.89 | TDP1 (0.54) | ATMALDH1A1KMT2ALMNAGLA | |
| SCHEMBL21975629 | 0.88 | ATM (0.46) | ATMALDH1A1KMT2ALMNAGLA | |
| SCHEMBL15148099 | 0.87 | ALDH1A1 (0.56) | ATMALDH1A1KMT2ALMNAGAA | |
| SCHEMBL21259176 | 0.87 | ATM (0.47) | ATMALDH1A1KMT2ALMNAGLA | |
| SCHEMBL166861 | 0.86 | ALDH1A1 (0.56) | ATMALDH1A1KMT2ALMNAGLA | |
| SCHEMBL3830833 | 0.85 | ATM (0.48) | ATMALDH1A1KMT2ALMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | claimed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | claimed |
| EP-4134134-A1 | STING AGONISTIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | claimed |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO., LTD. (CN) | 2021-02-09 | — | — | US | claimed |
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-11-12 | — | — | US | claimed |
| EP-3453714-B1 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | SUZHOU NEUPHARMA CO LTD (CN) | 2020-11-04 | — | — | EP | claimed |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-08 | — | — | US | claimed |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2020-03-19 | — | — | US | claimed |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-01-23 | — | — | US | claimed |
| US-10344048-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2019-07-09 | — | — | US | claimed |
| EP-3453714-A2 | CARDENOLIDE AND BUFADIENOLIDE 3-CARBONATE AND 3-CARBAMATE DERIVATIVES FOR THE TREATMENT OF CANCER AND COMPOSITIONS THEREOF | Suzhou Neupharma Co., Ltd (CN) | 2019-03-13 | — | — | EP | claimed |
| US-20170088580-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-03-30 | — | — | US | claimed |
| US-9018197-B2 | Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use | SUZHOU NEUPHARMA CO. LTD. (CN) | 2015-04-28 | — | — | US | claimed |
| CN-103619865-A | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO LTD | 2014-03-05 | — | — | CN | claimed |
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | claimed |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2012-08-02 | — | — | US | claimed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | claimed |
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2011085641-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO., LTD. (CN) | 2011-07-21 | — | — | WO | disclosed |
| EP-0476784-A1 | Processes for the preparation of ethers | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 1992-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354398-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | ATM 2168/4885ALDH1A1 290/4885KMT2A 2329/4885 |
| US-20170088580-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | ATM 2168/4885ALDH1A1 290/4885KMT2A 2329/4885 |
| US-10912784-B2 | Certain chemical entities, compositions, and methods | UGT2B7, BCCIP, ABCG2 | ATM 2316/4885ALDH1A1 422/4885KMT2A 3692/4885 |
| US-20120196842-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | ATM 2168/4885ALDH1A1 290/4885KMT2A 2329/4885 |
| US-10766920-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | ATM 2168/4885ALDH1A1 290/4885KMT2A 2329/4885 |
| US-20200024303-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, SGMS2 | ATM 2168/4885ALDH1A1 290/4885KMT2A 2329/4885 |
| US-20200085846-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | ATM 2316/4885ALDH1A1 422/4885KMT2A 3692/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | ATM 777/4885ALDH1A1 3607/4885KMT2A 3529/4885 |
| US-10344048-B2 | Certain chemical entities, compositions, and methods | TP53, VHL, SGMS2 | ATM 2168/4885ALDH1A1 290/4885KMT2A 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.